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Determinants of Patent Citations in Biotechnology: An Analysis of Patent 
Influence Across the Industrial and Organizational Boundaries 
 
 
 
ABSTRACT 
The present paper extends the literature investigating key drivers leading certain patents to 
exert a stronger influence on the subsequent technological developments (inventions) than 
other ones. We investigated six key determinants, as (i) the use of scientific knowledge, (ii) 
the breadth of the technological base, (iii) the existence of collaboration in patent 
development, (iv) the number of claims, (v) the scope, and (vi) the novelty, and how the effect 
of these determinants varies when patent influence—as measured by the number of forward 
citations the patent received— is distinguished as within and across the industrial and 
organizational boundaries. We conducted an empirical analysis on a sample of 5,671 patents 
granted to 293 US biotechnology firms from 1976 to 2003. Results reveal that the 
contribution of the determinants to patent influence differs across the domains that are 
identified by the industrial and organizational boundaries. Findings, for example, show that 
the use of scientific knowledge negatively affects patent influence outside the biotechnology 
industry, while it positively contributes to make a patent more relevant for the assignee’s 
subsequent technological developments. In addition, the broader the scope of a patent the 
higher the number of citations the patent receives from subsequent non-biotechnology patents. 
This relationship is inverted U-shaped when considering the influence of a patent on 
inventions granted to other organizations than the patent’s assignee. Finally, the novelty of a 
patent is inverted-U related with the influence the patent exerts on the subsequent inventions 
granted across the industrial and organizational boundaries. 
 
Keywords: patent influence; determinants; industrial boundary; organizational boundary; 
biotechnology. 
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1. INTRODUCTION 
The growing importance of technological innovation for firms as a source of a sustainable 
competitive advantage [e.g. 1, 2] has led researchers to identify indicators to measure the 
outcomes of R&D process. Great attention has been specifically paid to patent data, which has 
been one of the most widely used sources of data among researchers for the evaluation of 
R&D outputs [3, 4]. A patent, as defined by the United States Patent and Trademark Office 
(USPTO), is “a property right granted by the Government of the United States of America to 
an inventor to exclude others from making, using, offering for sale, or selling the invention 
throughout the United States or importing the invention into the United States for a limited 
time in exchange for public disclosure of the invention when the patent is granted”.1 The 
temporary monopoly granted to a patent’s assignee(s) (individuals, private or public 
organizations) generally lasts for 20 years. A patent is granted when it satisfies three main 
criteria: the invention the applicant aims to patent must (i) be novel, (ii) involve a non-
obvious inventive step, and (iii) be capable of industrial application.2 Several factors have 
contributed to the adoption of patent data for the aforementioned evaluation purposes [5]. 
First, patent data are available in most countries, especially in industrialized economies, 
where governments have collected data longitudinally. Second, patents contain a large amount 
of bibliographical information classified according to standardized schemes which in turn 
allows comparative analyses. Third, the extensiveness of data allows researchers and analysts 
to carry out both cross-sectional and longitudinal researches across multiple levels of analysis 
(e.g. nations, organizations, and individuals). 
 The potential of patent data to serve as an indicator of R&D outcomes has therefore 
attracted the attention of a large number of scholars. For instance, patent data have been 
proved capable to inform on different facets of the R&D process and outputs, such as the 
value of firms’ intellectual property [6], efficiency of R&D processes [7] and technological 
position in the competitive landscape [8], as well as to assess the impact of innovation 
policies [9]. Significant research efforts have been particularly channeled in assessing the 
impact of patents and identifying those factors leading some patents to exert a stronger 
influence on subsequent technological developments (as mainly measured by forward 
citations counting) than other ones [e.g. 3, 10-12]. Despite these intensive research we have 
                                                
1 The definition is reported in the USPTO Glossary available at www.uspto.gov/main/glossary. Other patent 
offices provide similar definitions. 
2 See the USPTO 2012 “Manual of Patent Examining Procedure” available at 
www.uspto.gov/web/offices/pac/mpep/.  
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however limited knowledge on how the antecedents of patent influence differently affect the 
impact patents exerted on subsequent technologies when this impact is analyzed in different 
domains. In other words, it is less well understood whether patent influence is more or less 
bounded within specific domains. In this regard, the present paper aims at contributing to the 
extant literature on the determinants of patent influence by investigating how six key 
determinants previously identified in the literature (i) the use of scientific knowledge, (ii) the 
breadth of the technological base, (iii) the existence of collaboration in patent development, 
(iv) the number of claims, (v) the scope of the patent, and (vi) the novelty—differently shape 
the impact of patents in four domains as those identified within and across the industrial and 
organizational boundaries. 
We conducted our empirical analysis on a sample of 5671 (granted) patents registered 
at the USPTO by 293 US biotechnology firms from 1976 to 2003. The biotechnology industry 
is a suitable setting for our research given the importance of patents as an effective mean for 
the protection of intellectual property in this context [see also 13, 14]. Results reveal that the 
effect of the considered determinants varies according to the domain under investigation. For 
example, it emerges that the use of scientific knowledge negatively affects the influence a 
patent exerts on subsequent technologies outside the biotechnology industry, while it 
positively contributes to make the patent technologically more relevant for the assignee’s 
future inventions; a patent of a broader scope impacts subsequent patents that are granted 
outside the biotechnology domains and to other firms, where its influence is positive and 
inverted U-shaped, respectively; the novelty of a patent has an inverted U-shape effect on  
patent influence across the industrial and organizational boundaries. 
 The remainder of the paper is organized as follows. Section 2 reviews the existing 
study investigating patent influence and describes the six main determinants we considered 
for our analysis. In Section 3, the research methodology is presented. Sections 4 and 5 report 
the results and discussion, respectively. Finally, Section 6 concludes the study. 
2. THEORETICAL BACKGROUND 
2.1. Measuring Patent Influence  
The skewness characterizing the distribution the influence of patents on the subsequent 
technological developments makes the design of evaluation measures and tools a complex 
activity [15, 16]. Many attempts have been made in the extant literature to provide useful 
empirical strategies focused on information strongly correlated with patent influence. Some of 
the earlier research [e.g. 17] focused, for example, on the estimation of patent influence as 
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reflected by the private value of patent rights, i.e. by analyzing the renewal data (e.g. patent 
renewals and renewal fee schedules). This approach has been subsequently validated and 
improved by several studies [7, 18]. The main logic underlying the adoption of renewal data 
is that the most valuable patents are those renewed to full statutory term, since renewing the 
patent protection for an additional year is expensive for the patent holders. However, this 
approach presents three main limitations [19]. First, for those patents renewed over their 
statutory lifetime, the renewal fees provide a lower rather than an upper bound for patent 
value. Second, this approach does not capture discontinuity in the patent value over its life 
until the patent reaches the maximum term. In fact, it is supposed that the annual returns from 
having the patent in force decrease monotonically over the patent life. Finally, renewal data 
provide information only on the part of patent value generally defined as patent premium [20], 
which represents the extra value that the invention generates to the assignee when it is 
patented. 
 We base our research on a complementary approach aimed at measuring the influence 
of patents on subsequent technological developments by the number of forward citations 
patents receive [e.g. 21, 22, 23]. The pioneering study by Trajtenberg demonstrated the 
existence of a positive and significant correlation between the social returns to innovation and 
forward citation indicators. Specifically, the author stated, “The cited patents opened the way 
to a technologically successful line of innovation [...]. Thus, if citations keep coming, it must 
be that the innovation originating in the cited patent had indeed proven to be valuable” [3: 
p.174]. Similarly, Albert et al. [24], focusing on the patents held by Eastman Kodak, showed 
the presence of a strong association between citation counts and the technical importance of 
patents. Patents’ technological relevance, as reflected by forward citations, has been also 
proved to positively affect economic-based indicators, thus strengthening the strategic 
importance of assessing patents’ technical performance. For example, Shane [25] found that, 
for a small sample of semiconductor firms, patents weighted by citations have more predictive 
power in a Tobin’s Q equation than simple patent counts. Citations-weighted patents also 
turned out to be more highly correlated with R&D than simple patent counts. By analyzing a 
set of German patented inventions, Harhoff et al. [10] found that patents with greater 
economic relevance were more likely to be cited in subsequent patents. Giummo [26] found 
similar patterns by examining the royalties received by the inventor(s) and patent holder(s) at 
nine major German corporations under the German Employee Compensation Act. Lanjouw 
and Schankerman [27] also used citations, revealing that they have significant power to 
predict which patents will be renewed and which will be litigated. Hall et al. [11] revealed the 
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existence of a positive relationship linking patent forward citations and the stock market 
valuation of firms’ intangibles, showing that an extra citation per patent boosts market value 
by 3%. Finally, Gambardella et al. [19] employed data from an extensive European survey 
and found that patents’ inventor economic return is significantly and positively correlated 
with the number of citations these receive. 
In order to provide a better understanding of the role played by forward citations as  
proxy of patent influence, it is worth analyzing in more details what a patent document means. 
As discussed, a patent awards to one or more assignee (individuals, private or public 
organizations) the right to exclude others from the unauthorized use of the disclosed invention 
for a predetermined period of time. Patent citations define and limit the scope of the property 
rights by indicating the technological base upon which a specific patent is built [11]. Patent 
citations are added by the applicant, even if the decision regarding which citations to include 
ultimately rests with patent examiners, who may thus create noise in assessing the impact of 
patents, especially when citations are used as a proxy of knowledge flows [11, 28, 29]. 
Nevertheless, despite this limitation, forward citations remain one of the most suitable 
indicators to assess the influence of patents.  
 Apart from ‘how’ measuring the influence of patents, a further question that has 
however received only scant attention in previous studies is ‘where’ measuring the influence. 
A patented invention may influence the technological landscape of subsequent inventions 
within or across the specific industry in which it is granted. For example, the case of Viagra, 
originally developed by Pfizer for cardiovascular applications, has found significant 
application for the treatment of erectile dysfunction; a similar pattern emerged in the 
Corning’s development of fiber optics, which have found important applications in the 
development of communication technologies [21]. On the other hand, the inventing firm or 
other organizations have exploited a patented technology to further develop technological 
solutions. The most classic example is represented by the ‘EMI CAT’ scanner created by the 
UK firm Electrical Musical Industries (EMI) Ltd. and then largely employed and refined by 
other companies that successfully dominated the market. Another case refers to Bowmar that 
invented the pocket calculator, which was however technologically exploited by Texas 
Instruments, Hewlett Packard and others [30]. Thereby, these cases highlight the importance 
to deepen our understanding of how patent influence varies across domains—identified by the 
industrial and organizational boundaries—to properly assess the impact of patented 
technological solutions as well as to design R&D strategies and policies aimed at maximizing 
the output of the inventing process. 
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2.2. Antecedents of Patent Influence  
Drawing from previous literature, we focus the attention on six determinants of the influence 
of patents: (i) the use of scientific knowledge, (ii) the breadth of the technological base, (iii) 
the existence of collaboration in patent development, (iv) the number of claims, (v) the scope 
of the patent, and (vi) the novelty. 
Scientific Knowledge: Scholars have discussed the significant contribution of science to 
economic growth for years [31, 32]. Research has demonstrated that knowledge flowing from 
public research organizations makes a considerable contribution to industrial innovations and, 
consequently, to welfare. For instance, Mansfield [33], analyzing 76 US firms in seven 
industries, found that 11% of product innovations and 9% of process innovations would not 
have been developed in the absence of recent academic research. Fleming and Sorenson [34] 
suggested that science functions as a map of the technological landscapes that can guide 
private research towards the most economically promising technological areas, thus avoiding 
wasteful experimentations. Nevertheless, regarding the relationship between the use of 
scientific knowledge (non-patent references) and patent impact, contrasting results can be 
found [35]. While Henderson et al. [36] and Mowery et al. [37] found that academic patents 
receive more citations than non-university patents, thus confirming the importance of 
scientific knowledge as input in the inventing process, other authors have provided divergent 
results, showing that links to science exert different effects on the impact of resulting patents 
according to the firm’s industry, the inventive problems to be addressed, and the level of 
analysis (firm or patent) [34, 38, 39]. 
Breadth of Technological Base: Scholars have emphasized that innovativeness often depends 
on firms’ ability to search for knowledge widely [e.g. 23, 39], since a broader search increases 
the likelihood of discovering new and useful knowledge combinations [40]. However, the 
search process is highly path-dependent and constrained by organizational routines [41], 
hence leading organizations to search for knowledge locally, i.e., into the neighbor of their 
existing capabilities [42]. The relationship between searching widely and patent influence has 
been extensively discussed. For example, by analyzing the innovation processes in the optical 
disk industry, Rosenkopf and Nerkar [23] found that patented innovations reflecting broader 
search efforts also have a greater impact on subsequent technologies. Using data on over half 
a million patents, Singh [43] revealed that patents based on a broad range of technologies 
present a higher quality. Finally, Capaldo and Messeni Petruzzelli [44] showed the positive 
impact exerted by the number of different knowledge domains across which firms search on 
the number of forward citations received by their patents. A broader search involves new 
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interaction between the components, thus constituting the basis for a broader range of 
subsequent innovative developments and contributing to the pace of the technological 
progress [45]. A broader search process may also expand the patent life, then increasing the 
monopolistic rents of the holder organization [46]. However, increasing the breadth of 
technological search may have harmful consequences on the development of successful 
inventions. In fact, searching widely is a risky process that may lead to uncertain and 
unpredictable outcomes. Furthermore, searching across and combining a great variety of 
technological components may create several difficulties due to a lack of absorptive capacity, 
common knowledge base, and inexperience or unfamiliarity with the recombined technologies 
[47].  
Joint Development: Developing innovation can be conceived as a process where 
complementary and heterogeneous inputs (i.e., pieces of knowledge) are transformed into 
outputs (i.e., results of innovations) [48]. The increasing complexity of the knowledge-
creation processes has lead firms to rely upon external resources [49] and hence search 
beyond their own organizational boundaries for valuable knowledge and skills 
complementing their capabilities [50]. In fact, innovation partly depends on firm-specific 
knowledge resources and strongly depends on determinants external to the firm. This is 
because firms often specialize in one or few fields of knowledge and rarely have all the 
required resources internally. Therefore, to innovate successfully, firms need to collaborate to 
gain access to knowledge resources that are not internally available [51]. Collaborations allow 
organizations to expand their knowledge base and, thus, to explore new opportunities and 
solutions [52], which in turn may lead to the development of technologically valuable 
innovations [e.g. 53]. Nevertheless, despite these advantages, collaborations may also hamper 
the result of the innovation process due to the emergence of opportunistic behaviors and 
differences between partners’ bargaining power [e.g. 54]. This may increase competition and 
reduce the benefits going along with inter-organizational resource integration. Inter-
organization collaborations at the patent level may be captured by analyzing the presence of 
co-assignees, i.e. whether patent property rights are jointly shared between two or more 
organizations [55, 56]. Co-owned patents may assume an important role in industries with 
strong regimes of appropriability, such as chemical, pharmaceutical, and biotechnology [55]. 
In addition, joint patents are largely the result of inter-organizational collaborations where the 
companies are unable to ‘divide’ the invention among the partners, hence creating the 
necessity to share the intellectual property [57]. 
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Claims: The claims reported in patent documents define the legally enforceable aspects of the 
given invention. Patent claims can be distinguished as principal and subordinate. The former 
defines the essential novel features of the invention, whereas the latter describes detailed 
features of the innovation. The number of claims can affect patent influence: the broader the 
property rights protection the higher the probability that others will rely upon the invention. 
This explains the incentive leading assignees in increasing the number of claims in the patent 
application [58]. Tong and Frame [59] were the first to use information on claims to conduct 
empirical analysis. Specifically, they investigated the relationship between the number of 
claims reported in patents and several macroeconomic (nation-level) indicators of 
technological development. Later, Lanjouw and Schankerman [27] adopted the information 
on claims to test their influence on the likelihood of challenge and validity suits for a sample 
of US patents. Recently, Bonaccorsi and Thoma [60] employed the number of patent claims 
as an indicator to analyze how the quality of patents varies across different communities of 
inventors.  
Scope: One of the most discussed determinants of patent impact is represented by its 
technological scope. The scope of a patent may be an important determinant of the efficacy of 
patent protection [61]. In their pioneering study, Merges and Nelson evidenced how “[...] the 
broader the scope, the larger the number of competing products and processes that will 
infringe the patent [...]” [62: p. 839], thus increasing the technological influence of the patent. 
The relevance of the scope to enhance patent influence has been also investigated by several 
empirical works. For instance, Lerner [63] demonstrated that the patent scope has a significant 
and positive effect on the valuation of venture capitalists financing biotechnology start-ups. 
Shane [64], conducting an extensive analysis of 1,397 patents assigned to the Massachusetts 
Institute of Technology, showed that the scope of patents increases the likelihood of the 
relative inventions to be commercialized.  
Novelty: One of the central concepts in the innovation study is that refining and improving an 
existing technology and introducing a new approach to technical practices are fundamentally 
different things [65]. The development of novel technologies is generally associated with the 
first stage of the technology life-cycle, being thus characterized by market uncertainty and 
R&D efforts [66]. However, if successful, technologies coming through this phase and 
moving to the growth stage have more opportunities to become radical innovations, hence 
breaking existing technological paradigms [64], shifting towards new trajectories, and 
representing the basis on which further innovations are built. Therefore, novel patented 
innovations may represent rare, valuable, and inimitable sources of competitive advantage for 
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firms [67], allowing business growth and new business development [13]. Such an advantage 
mainly derives from the benefits associated with learning economies [68], causal ambiguity 
[69], switching costs [70], consumer learning, and reputation advantages [71]. Nevertheless, 
as discussed, developing a novel patented innovation is an uncertain and risky task [72]. 
Environmental factors, such as the pace of technology and market evolution [73], may also 
affect the relevance of such novel technical solutions. In particular, technological uncertainty 
makes buyers reluctant to invest in product-specific competencies [70, 71, 74], with the 
consequent risk of introducing an underdeveloped product that will make final customers 
more willing to switch to alternative products [75]. In addition, market evolution may imply 
changes in consumer tastes or preferences, emergence of new regulations, degree of market 
fragmentation, and consumer learning [76], which may in turn impact the diffusion and 
success of a novel patented innovation. 
3. METHODS 
3.1. Research Setting and Sample Data 
We conducted out empirical analysis on the US biotechnology industry. The rise of 
biotechnology has its origins in the discovery of the double helix structure of DNA by Watson 
and Crick in 1953 and the subsequent development of DNA recombination by Cohen and 
Boyer in 1973. The latter can be considered a radical innovation process that broke the 
barriers of entry into the pharmaceutical industry [77, 78]. We chose this particular research 
setting since the biotechnology industry is one of the most innovation-intensive industries 
[79], and the patenting activity within this context plays a critical strategic role for firms’ 
performance [80-82]. We focus our attention on the US market representing the most 
significant center of innovation for biotechnology [14, 80, 83]. For instance, in 2006, the US 
market was revealed as the market with the highest concentration of dedicated biotechnology 
firms, which spent US$25,101 million on R&D, accounting for 75% of total biotechnology 
R&D expenditures in developed countries [84].  
One of the major criticisms advanced against the adoption of patent data is represented 
by the unobserved heterogeneity across industries and technology fields [85], which can 
significantly affect the suitability of patents as indicators of R&D outcomes. However, in the 
biotechnology field, innovations are more discrete in terms of product fragmentation, and, 
hence, may be covered by a small number of patents [80]. Individual patents can yield 
substantial rents from commercialization and/or licensing. For this reason, firms operating in 
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this industry are likely to dedicate significant resources on the writing of strong and relevant 
patent applications. This supports the use of patent data as a proxy of the R&D outcomes. 
 For the empirical analysis, we relied on a patent dataset drawn from a population of 
358 US public and private firms included in the BioScan database in 2010. BioScan is one of 
the most recognized biotechnology industry reporting services [13]. We searched for patents 
firms filed under the US patent system during the observation period 1976–2003 by querying 
the USPTO database.3 We included in the sample only those firms that granted at least one 
biotechnology patent in the observation period—we identified the industrial boundary by 
using the US patent technological classes [86].4 This reduced the sample of firms from 358 to 
293. Those firms granted 5671 patents, which represent our final sample and unit of analysis.5 
For each patent, we collected bibliographical data and backward and forward patent citations. 
Analyzing distribution of patents across the firms in our sample (see Figure 1), Genentech, 
Pioneer Hi-Bred, and Chiron emerge as the main players in terms number of patents (14.44%, 
12.03%, and 10.67%, respectively). 
Genentech
14.44%
Pioneer Hi-Bred
12.03%
Chiron 
10.67%
Human Genome 
Sciences
6.14%
Amgen
5.15%
ZymoGenetics
4.94%
Genencor
3.91%
Affymetrix
3.10%
New England 
BioLabs
2.15%
Maxygen
1.30%
Cytokinetics
1.25%
Other firms
34.91%
 
Figure 1. Distribution of biotechnology patents across the firms in the sample. 
                                                
3 We selected the 1976–2003 period for the following reasons. First, the conceptualization and development of 
the key operational principles of biotechnology paradigm, that are the genetic engineering and monoclonal 
antibodies, started in early 1970s and first venture capitalists recognized the utility of these techniques in the late 
1970s [78]—for example, Genentech, the first new biotechnology firm, was founded in 1976. Second, the 
USPTO allows electronic search for patents starting from 1976. Finally, since the data were collected in 2009, 
we ended the observation period in 2003 in order to allow the patents to be cited in an equal five-year time 
window. 
4 Building on previous studies [86], the boundaries of the biotechnology domain were defined using the 
following three-digit US technological classes: 424, 435, 436, 514, 530, 536, 800, 930, and PLT. 
5 The number of patents grown rapidly from 1976 up to 2003 with a peak of 981 and 739 patents in 1995 and 
2000, respectively. 
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3.2. Variables 
Dependent Variables: As discussed in the previous section, we estimated the influence of a 
patent on subsequent technologies as the number of forward citations the patent received [3, 
4, 15, 60, 87]. The use of forward citations is particularly suitable for our study, since 
citations added by examiners do not represent a critical issue for two main reasons. First, we 
analyze the biotechnology context, where the share of applicants attributed forward citations 
is on average greater than 70% [28] and assignees strategically withhold only 5–7% of 
forward citations [29]. Second, we rely on patents granted by the USPTO to US firms, hence 
further reducing the share of examiner citations, which has been proven to be especially high 
among foreign firms [28].6 To control for the fact that older patents have a higher likelihood 
of being cited by following patents, we considered only those citing patents filed within a 
five-year time window after the given patent’s filing date [42].  
With the aim to disentangle the influence of patents across different domains, we 
distinguished it according to the industrial (biotechnology) and organizational boundaries (see 
Figure 2). Firstly, we considered the whole patent influence (Influence), which was measured 
by the number of forward citations a patent received from subsequent patents. Following 
previous research [3, 87], the whole influence of the patent i (1,2,…,m) is assessed as follows: 
!
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where t (1976,…,2003) refers to the i-th patent’s filing year and Citi,t is the number of forward 
citations the i-th patent received from following patents up to five years after the filing date. 
Secondly, we classified patent influence as within (InfluenceInBio) and outside 
(InfluenceOutBio) the boundary of the biotechnology industry [4, 23]. In particular, a patent 
citing the given patent i is classified as inside the biotechnology industry if it is assigned to at 
least one of the nine US technology classes defining the boundary of the biotechnology 
industry (see footnote 4), otherwise it is classified as outside the biotechnology. Thus, a 
patent’s influence within and outside the industrial boundary is evaluated as: 
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6 The share of examiners’ citations in our sample of patents, which may be accounted for only the 410 patents 
granted after 2000, is about 22% of the overall number of forward citations. 
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where t (1976,…,2003) refers to the i-th patent’s filing year and CitInBioi,t and CitOutBioi,t 
represent the number of forward citations the i-th patent received by the subsequent patents 
assigned inside and outside the biotechnology industry within a 5-year time window, 
respectively. Finally, referring to the organizational boundary, the influence of a patent is 
distinguished into InfluenceInFirm and InfluenceOutFirm if the citing patent is granted to the 
same assignee as the given patent or to a different one [4, 88]. Therefore, we adopted the 
following measures:  
!
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#
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&
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,, 1
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t
titi CitInFirmnFirmInfluenceI
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where t (1976,…,2003) refers to the i-th patent’s filing year and CitInFirmi,t and CitOutFirmi,t 
represent the number of forward citations the i-th patent received by the subsequent patents 
granted to the same firm assignee or other assignees within a 5-year time window, 
respectively.  
 
 
Figure 2. Patent influence across the industrial (biotechnology) and organizational boundaries. 
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To validate our patent influence indicators, we conducted a robustness test by 
analyzing the distribution of the family size of patents, which has been proven to be an 
alternative predictor of the relevance underlying an invention [27, 89]. Specifically, we 
referred to family size as “the number of different patent systems in which protection for a 
single invention is sought” [89: p. 2]. Thus, even though family size is not suitable for the 
purpose of the present paper, since it does not allow patent influence to be distinguished 
across multiple domains, we compared our citation-based measure with patent family size. 
We found our measures of patent influence strongly related to family size, thus bestowing 
further confidence on our choice. 
 
Independent Variables: To account for the use of scientific knowledge (ScienKnowledge) in 
the inventing process, we measured the number of scientific non-patent references the given 
patent cited. The number of non-patent backward citations is a suitable measure to evaluate 
the extent to which a patent is based on scientific knowledge [10, 90].7 To measure the 
breadth of the technological base (TechBreadth) upon which the given patent is built, we 
relied on the measure proposed by Jaffe and Trajtenberg [4]. The construction of this measure 
follows three steps: (i) identification of all citations made by the given patent i, (ii) 
identification of the technological classes assigned to the cited patents and (iii) computation 
of the index equal to one minus the Herfindahl concentration index. Thus, it results in the 
following equation: 
, 
∑ − = 
n 
j 
ij s TechBreadth 2 1 
 
where sij refers to the fraction of patents cited by patent i that belong to technological class j 
out of n technological categories assigned to the patents by the USPTO. Specifically, we refer 
to the three-digit classes [91]. Since this variable cannot be defined when there are no 
backward citations, in this case, technological breadth is set equal to zero. The joint 
development of patents (JointDevelopment) was computed by counting the number of co-
applicants to which the patent was granted [35, 55].8 To account for the effect exerted by 
claims, we measured the number of claims per patent (Claims) [19, 27, 59]. Following the 
approach proposed by Lerner [63], we measured the scope of a patent (Scope) as a time-
                                                
7 Results are confirmed when we measured the use of scientific knowledge as a dummy variable taking value 
one if the focal patent cites at least one non-patent reference, and zero otherwise. 
8 Inter-organizational collaborations were measured also as a dummy variable taking value one if the focal patent 
is assigned to more than one firm, and zero otherwise. The results did not significantly changed. 
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invariant count of the number of three-digit technological classes the USPTO assigned to the 
patent [10]. Finally, the novelty of a patent (Novelty) was evaluated as the number of three-
digit technological classes in which patents cited by the patent are found, but the patent itself 
is not classified [64].  
 
Table 1. Definitions of the dependent, independent, and control variables. 
Variable Description 
Dependent variables  
Influence Number of citations a patent received  
InfluenceInBio Number of citations a patent received from patents within the 
biotechnology domain 
InfluenceOutBio Number of citations a given patent received from patents outside the 
biotechnology domain 
InfluenceInFirm Number of citations a patent received from patents granted to the 
same assignee 
InfluenceOutFirm Number of citations a patent received from patents granted to a 
different assignee 
  
Independent variables  
ScienKnowledge Number of non-patent references a patent cited 
TechBreadth Breath of the technological base upon which a patent is built 
JointDevelopment Number of patent co-applicants  
Claims Number of patent claims 
Scope Number of US three-digit technological classes assigned to a patent 
Novelty Number of US three-digit technological classes in which patents 
cited by a patent are found, but wherein the patent itself is not 
classified 
  
Control variables  
FirmPatents Number of patents the assignee filed at the USPTO during a five-
year time window preceding the filing date of the given patent 
FirmAge Number of years elapsed between the assignee’s year of 
incorporation and the filing year of the given patent  
TeamSize Number of inventors involved in a patent 
BackCitations Number of patent backward citations 
CitAge Coefficient of variation (standard deviation/mean) of the number of 
years elapsed from the filing date of the cited patents to the filing 
date of a patent  
GovInt Dummy variable that takes value one if a patent was funded by the 
U.S. government, zero otherwise 
SIC Code Dummy variable indicating the main assignee’s SIC code 
Year Dummy variables indicating a particular year in the observation 
period (1976–2003 period) 
Note: Influence, InfluenceInBio, InfluenceOutBio, InfluenceInFirm, and InfluenceOutFirm 
variables count the number of citations a patent received within a five-year time window. 
 
Control Variables: We also included several control variables that may explain patent 
influence. First, we controlled for firms’ patent stock (FirmPatents), which is used to take 
into account the technological capital owned by the biotechnology firm to which the given 
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patent is granted [13, 14, 92]. The firm’s patent stock was measured as the number of patents 
the firm granted at the USPTO during a 5-year time window preceding the filing date of the 
given patent. Second, we controlled for the firm’s age (FirmAge) as the number of years 
elapsed between the firm’s year of incorporation and the patent’s filing year [79]. Third, the 
size of the team involved in a patent’s development can have a direct effect on its relevance, 
because of economies of specialization, a larger and more diverse pool of knowledge, and 
access to a wider and more heterogeneous external network. Therefore, we included the 
number of inventors involved in the given patent (TeamSize) [43]. Fourth, we controlled for 
the patent’s number of backward citations (BackCitations) [10]. Fifth we controlled for the 
age of the patents the focal patent cited, i.e. the number of years elapsed from the filing date 
of the cited patents to the filing date of the focal patent. We specifically included a variable 
(CitAge) measuring the coefficient of variation (standard deviation/average) of the age of 
cited patens.9 Sixth, we controlled whether a patent was financially supported by the US 
government (GovInterest). This was evaluated by a dummy variable that takes a value one if 
the given patent was funded by US governmental agencies and zero otherwise. Finally, we 
also included dummy variables (33) for the main SIC codes assigned to the patents’ assignees 
and year dummies (26). Table 1 summarizes our variables. 
3.3. Estimation Procedure 
The dependent variables are count variables, taking only integer and positive values. Thus, the 
use of linear regression modeling is inadequate since the distribution of residuals will be 
heteroskedastic non-normal. In this case, the use of a Poisson regression approach is 
preferred. This estimation however assumes the mean and variance to be equal while patent 
data often present over-dispersion, i.e. the variance exceeds the mean [93]. The over-
dispersion is confirmed by the coefficients of variation equal to 2.30, 2.66, 4.22, 2.77, and 
2.82 for Influence, InfluenceInBio, InfluenceOutBio, InfluenceInFirm, and InfluenceOutFirm, 
respectively. Therefore, as for previous studies [e.g. 23], we found the negative binomial 
estimation as more suitable to our data—this specification can handle over-dispersion since it 
allows the variance to differ from the mean [93]. The negative binomial estimation considers 
a variable yi that follows a Poisson regression model with parameter λi and omitted variable ui 
such that exp(ui) follows a gamma distribution with mean one and variance α: 
 
                                                
9 By introducing the coefficient of variation of the age of cited patents we further reduced the risk of 
multicollinearity issues in the regression models since the average and standard deviation tend to be correlated—
in our data the correlation between the average and standard deviation of the age of cited patents is equal to 
0.530. 
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The φi is the vector of the parameter associated with the vector of independent variables xi and 
α is the over-dispersion parameter. We reported the model specification in the following: 
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 where i=1, …, 5,671, εi is the error term, and [β1, …, βm, δ1, …, δk] is vector of the parameter to 
estimate—βm refers to the independent variables (IndepVar) and δk refers to the control 
variables (ContrVar). The models were estimated through the “nbreg” routine in the STATA 
10.0 software package. Significance levels are based on Huber-White robust standard errors. 
4. RESULTS 
Table 2 report the descriptive statistics and correlation between our variables. Correlations 
among the independent variables are low such that multicollinearity can be considered to be 
not a cause for concern. We also standardized the independent variables before creating the 
squared terms and running the regression. The standardization reduces potential 
multicollinearity issues in the estimation process when testing the curvilinear effect of an 
independent variable [94]. 
 In Table 3, we reported the results of the negative binomial estimations of patent 
influence across the different domains identified by the industrial and organizational 
boundaries: Model 1 report the analysis for patent Influence, whereas Models 2–5 test patent 
influence as distinguished in InfluenceInBio, InfluenceOutBio, InfluenceInFirm, and 
InfluenceOutFirm, respectively. We reported the estimation of the over-dispersion parameter 
alpha (α) for each model. The results confirm the negative binomial estimation to be more 
suitable than the Poisson one since the estimated over-dispersion parameter is significantly 
different from zero in each model. In addition, when the squared term of an independent 
variable was found not statistically significant in the regression model, we ran another 
regression excluding this term. This allowed us to obtain better estimates by further reducing 
the risk of multicollinearity issues. 
 Model 1 provides evidence that the number of claims (Claims, β = 0.1896, p < 0.001; 
Claims2, β = -0.0061, p < 0.001) and the novelty of a patent (Novelty, β = 0.2658, p < 0.001; 
Novelty2, β = -0.0423, p < 0.1) are curvilinearly (inverted-U) related with the patent’s 
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influence. The results are different when analyzing the influence within the biotechnology 
domain (Model 2). Specifically, while the inverted U-shape effect of the number of claims 
(Claims, β = 0.1866, p < 0.001; Claims2, β = -0.0059, p < 0.001) is in line with the 
relationships we found for Influence (Model 1), the involvement of more than one firm in the 
development of a patent (JointDevelopment, β=0.0960, p < 0.1) also exerts a positive effect 
on the number of citations the patent receives from subsequent domain-specific 
(biotechnology) patented inventions. Model 3 reveals that both ScienKnowledge (β = -0.0022, 
p < 0.001) and TechBreadth (β = -0.0419, p < 0.1) negatively affect the influence of a patent 
on subsequent patents granted outside the industrial boundaries (ValueOutBio). Differently, 
Claims (β = 0.0645, p < 0.01) and Scope (β = 0.0762, p < 0.001) show a positive impact on 
InfluenceOutBio. Finally, the novelty (Novelty, β = 0.4590, p < 0.001; Novelty2, β = -0.0467, p 
< 0.001) curvilinearly affects (inverted-U) the influence the patent exerts on subsequent 
invention outside the industry domain. In Model 4, we tested the determinants of patent 
influence within the assignee’s organizational boundaries. The use of scientific knowledge 
(ScienKnowledge , β = 0.0014, p < 0.01) is positively related with InfluenceInFirm, whereas 
the number of claims (Claims, β = 0.1650, p < 0.001; Claims2, β = -0.0045, p < 0.001) 
confirms the inverted-U shaped effect supported in Model 1 and Model 2. In Model 5, the 
effect of the antecedents on the impact of patents across the assignee’s organizational 
boundaries is tested. The results show the number of claims (Claims, β = 0.1648, p < 0.001; 
Claims2, β = -0.0061, p < 0.001), the scope (Scope, β = 0.0517, p < 0.1; Scope2, β = -0.0174, p 
< 0.05), and the novelty measure (Novelty, β = 0.2905, p < 0.001; Novelty2, β = -0.0413, p < 
0.001) exerting a non-monotonic impact (inverted-U) on the number of citations the patent 
received from companies other than that of the assignee. Finally, referring to the control 
variables, it is worth noting the positive effect of the number of inventors (TeamSize) and the 
negative impact of the coefficient of variation of the age of the cited patents (CitAge) on 
patent impact in the different domains, except for patent influence across the industrial field 
(Model 3) and within the organization context (Model 4). 
5. DISCUSSION 
Overall, we revealed that the six key determinants we analyzed differently contribute to 
explain the influence of patents as this is decomposed according to the industrial and 
organizational boundaries. Table 4 summarizes the main results. Figure 3 reports the slope 
analysis and plots the relationships between the six determinants and patent influence. 
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Table 2. Descriptive statistics and correlation matrix (N = 5671). 
Variable 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
1. Influence 1.000 
        
         
2. InfluenceInBio 0.974 1.000 
       
         
3. InfluenceOutBio 0.508 0.301 1.000 
      
         
4. InfluenceInFirm 0.570 0.562 0.263 1.000 
     
         
5. InfluenceOutFirm 0.980 0.953 0.505 0.393 1.000 
    
         
6. ScienKnowledge 0.022 0.025 0.000 0.037 0.016 1.000 
   
         
7. TechBreadth 0.074 0.055 0.104 0.027 0.076 0.224 1.000 
  
         
8. JointDevelopment -0.004 0.002 -0.026 -0.017 -0.001 0.043 0.045 1.000 
 
         
9. Claims 0.024 0.015 0.043 0.046 0.015 0.106 0.041 0.011 1.000          
10. Scope 0.079 0.056 0.120 0.025 0.082 0.054 0.147 0.028 0.062 1.000         
11. Novelty 0.090 0.043 0.221 0.041 0.092 0.427 0.429 0.007 0.088 0.072 1.000        
12. FirmPatents -0.117 -0.097 -0.121 -0.047 -0.119 0.072 0.012 -0.015 0.002 0.044 -0.149 1.000       
13. FirmAge -0.068 -0.048 -0.104 0.053 -0.089 -0.089 -0.099 -0.064 -0.077 0.003 -0.174 0.201 1.000      
14. TeamSize -0.001 -0.005 0.018 -0.011 0.002 0.080 0.075 0.221 0.118 0.063 0.073 0.010 -0.140 1.000     
15. CitAge 0.030 0.017 0.064 0.022 0.029 0.104 0.430 0.035 0.072 0.051 0.277 -0.121 -0.110 0.071 1.000    
16. BackCitations 0.053 0.023 0.136 0.036 0.051 0.534 0.289 -0.012 0.128 0.090 0.572 -0.103 -0.134 0.069 0.224 1.000   
17. GovInterest 0.040 0.022 0.083 0.032 0.037 0.015 0.026 0.129 0.010 0.012 0.026 -0.071 -0.073 0.092 0.013 0.007 1.000 
                  Mean 10.25 9.80 2.45 2.03 8.22 31.23 0.532 0.099 20.09 2.273 4.062 109.8 20.11 3.004 0.351 9.138 0.033 
Std. Dev. 25.93 23.42 6.13 5.63 23.16 48.53 0.293 0.315 21.73 0.998 6.553 131.1 22.20 2.021 0.383 19.61 0.180 
Min 1 1 1 1 1 0 0 0 0 1 0 0 0 1 0 0 0 
Max 305 296 62 71 266 438 0.931 2 683 8 63 531 137 27 11.56 259 1 
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Table 3. Negative binomial regression on patent influence across different domains (N = 5671). 
 Model 1 (Influence) 
Model 2 
(InfluenceInBio) 
Model 3 
(InfluenceOutBio) 
Model 4 
(InfluenceInFirm) 
Model 5 
(InfluenceOutFirm) 
Independent variables           ScienKnowledge 0.0004 (0.0005) 0.0008 (0.0005) -0.0022*** (0.0005) 0.0014** (0.0005) 0.0002 (0.0005) 
TechBreadth 0.0018 (0.0331) 0.0400 (0.0322) -0.0419† (0.0215) 0.0280 (0.0240) -0.0147 (0.0417) 
JointDevelopment 0.0803 (0.0539) 0.0960† (0.0545) 0.0143 (0.0528) -0.0106 (0.0589) 0.0814 (0.0540) 
Claims 0.1896*** (0.0236) 0.1866*** (0.0236) 0.0645** (0.0215) 0.1650*** (0.0237) 0.1648*** (0.0243) 
Claims2 -0.0061*** (0.0010) -0.0059*** (0.0010)   -0.0045*** (0.0010) -0.0061*** (0.0011) 
Scope 0.0153 (0.0206) -0.0051 (0.0213) 0.0762*** (0.0170) -0.0099 (0.0199) 0.0517† (0.0289) 
Scope2         -0.0174* (0.0088) 
Novelty 0.2658*** (0.0486) 0.0461 (0.0488) 0.4590*** (0.0471) 0.0690 (0.0547) 0.2905*** (0.0520) 
Novelty2 -0.0423*** (0.0062)   -0.0467*** (0.0062)   -0.0413*** (0.0064) 
Control variables           
FirmPatents -0.0211 (0.0260) -0.0172 (0.0266) -0.0044 (0.0215) -0.0904*** (0.0230) -0.0157 (0.0288) 
FirmAge -0.0013 (0.0033) -0.0016 (0.0033) -0.0076** (0.0028) -0.0043 (0.0029) 0.0008 (0.0035) 
TeamSize 0.0625*** (0.0169) 0.0674*** (0.0170) 0.0089 (0.0184) 0.0307 (0.0199) 0.0680*** (0.0184) 
CitAge -0.1416** (0.0457) -0.1450** (0.0455) -0.0589 (0.0450) 0.0572 (0.0628) -0.1907*** (0.0544) 
BackCitations 0.1030* (0.0468) 0.1917*** (0.0579) 0.0352 (0.0462) -0.0316 (0.0526) 0.0855* (0.0431) 
BackCitations2   -0.0211*** (0.0037)       
GovInterest -0.0431 (0.0954) -0.0087 (0.0986) 0.0862 (0.0983) 0.1699 (0.1102) -0.0973 (0.0961) 
SIC Code Included Included Included Included Included 
Year Included Included Included Included Included 
Intercept  2.9711*** (0.3750) 2.2830*** (0.3791) 3.1207*** (0.3275) 1.0649** (0.3272) 2.7858*** (0.4049) 
Log pseudo-likelihood  -18122.71 -17527.43 -10090.10 -12213.85 -16793.01 
Degree of freedom 63 63 62 62 64 
Alpha (over-dispersion) 0.916*** (0.030) 0.912*** (0.031) 0.397*** (0.021) 0.647*** (0.025) 0.908*** (0.042) 
Notes:  †p < 0.1; *p < 0.05; **p < 0.01; ***p < 0.001; 
Huber-White robust standard errors in parentheses; 
The hypothesis test for the over-dispersion is that the alpha parameter is zero. 
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We specifically found that the use of scientific knowledge negatively affects a patent’s 
impact on subsequent patents that are granted outside the biotechnology industry, while it 
increases the technological relevance of the patent for the assignee’s future inventions. A 
more extensive use of scientific knowledge may provide assignees with a broader knowledge 
base to source for subsequent inventions [34, 95]. On the other hand, the negative effect of the 
use of scientific knowledge on the number of citations a patent receives from subsequent non-
biotechnology patents may be due to the greater complexity that features patents building on a 
broader scientific knowledge base [39]. This in turn contributes to reduce the degree of 
understanding and applicability in sectors other than biotechnology. 
 
Table 4. Determinants and main effects on patent influence. 
 Influence InfluenceInBio InfluenceOutBio InfluenceInFirm InfluenceOutFirm 
ScienKnowledge n.s. n.s. - + n.s. 
TechBreadth n.s. n.s. - n.s. n.s. 
JointDevelopment n.s. + n.s. n.s. n.s. 
Claims ∩ ∩ + ∩ ∩ 
Scope n.s. n.s. + n.s. ∩ 
Novelty ∩ n.s. ∩ n.s. ∩ 
Note: “n.s.” indicates that the effect of the determinant on the patent influence was not significant (p > 0.1). 
 
Findings also show that the breadth of technological base generally does not 
significantly affect the influence a patent exerts on subsequent technological developments. In 
other words, the analysis suggests that combining knowledge across either multiple or few 
domains does not significantly contribute to enhancing the impact of the resulting patented 
invention. This result may be explained by the research on knowledge search and 
recombination process according to which most innovative firms are those performing a 
balanced search process [34, 41]. In fact, on the one hand, excessive complexity [96] and lack 
of absorptive capacity [47], and, on the other hand, a limited set of technological opportunities 
to be combined [40] may, respectively, undermine search efforts towards the development of 
significant inventions. Nevertheless, a different result emerges when referring to a patent 
influence outside the biotechnology industry where a patent’s technological breadth exerts a 
negative effect on the citations the patents receives from non-biotechnology patents. The costs 
of going along with complexity seem to outweigh the benefits of multiple recombinant 
possibilities, by significantly reducing the capability of organizations operating in different 
industrial domains to build on the technological solutions posed by such patented inventions 
[97].  
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Figure 3. Determinants of patent influence (ceteris paribus, only significant relationships are 
reported, i.e. p<0.1). 
 
  The joint development of a patent presents a significant effect only when referring to 
the influence of the patent within the biotechnology domain. This effect is positive and may 
be closely related to the nature of the patent in our sample. The majority of joint patents 
(about 90%) occur between biotechnology firms or between biotechnology firms and large 
pharmaceutical companies. Being highly focused on specific strategic issues, these patents 
may result of interest especially to those firms operating within the biotechnology. This 
finding is in line with a recent study by Zidorn and Wagner [98], who found that alliances in 
the biotechnology industry are generally established to specialize in a certain research field, 
rather than to explore and enter into new markets and domains, hence making the influence of 
their innovative outcomes generally bounded within biotechnology.  
The effect of the number of claims on the future citations a patent receives is 
curvilinear (inverted-U) in all the considered domains - except for the influence the patent 
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exerts outside biotechnology, where the impact is linear and positive. Results suggest that as 
the number of original functionalities a patent claims increases the uncertainties associated 
with the domain of application of the patent also increase [99]. This may therefore reduce the 
probability that the patent is used as a valuable source for the subsequent technological 
developments. 
 The results on scope suggest the presence of a curvilinear effect on patent influence 
outside the assignee’s organizational domain. The effect is however linear and positive on 
patent influence outside biotechnology. As expected, a patent of a wide industrial 
applicability is more likely to find successful applications outside the specific organizational 
and industrial domains, although in the former a trade-off emerges. This finding seems to 
suggest that a patent with a broader scope may be the result of specific strategic choices rather 
than innovativeness of the given patent per se [62]; thus, the patent may result in being 
technologically less valuable for other organizations.  
 Finally, the last determinant we investigated is the novelty of patents, that is, the 
extent to which the patent differs from the state of the art. Our analysis shows that its effect is 
curvilinear on patent influence as a whole and patent influence across the industrial and 
organizational boundaries. This suggests that a high degree of novelty may slow down the 
diffusion of the patented invention [73]. In fact, other firms, also operating outside the 
biotechnology industry, may encounter difficulties in absorbing and using the novel invention 
since their different and distant technological competences and knowledge bases. This may 
therefore hinder those firms’ capability in innovating by following the new traced directions. 
6. CONCLUDING REMARKS 
In this paper, we put forward potential estimates of patent influence on subsequent 
technological developments: (i) the use of scientific knowledge, (ii) the breadth of the 
technological base, (iii) the existence of collaboration in patent development, (iv) the number 
of claims, (v) the scope of the patent, and (vi) the novelty. We measured patent influence as 
the number of citations received by subsequent patents. Citations were distinguished across 
four domains identified by the industrial and organizational boundaries. The results, based on 
an empirical analysis of 5671 biotechnology patents from 1976 to 2003, revealed that the 
contribution of the estimates to patent influence varies as the different domains of impact are 
considered.  
 Our study contributes to the research on patent estimation in three main ways. First, 
we conducted a multi-dimensional analysis of patent influence by differentiating the impact 
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patents exerted within and outside its industrial domain and within and across the assignee’s 
organizational boundaries. This shed more light on the meaning of patent influence on 
subsequent patented technologies, hence providing a better comprehension of how inventors 
and organizations may focus their resources on the different determinants according to the 
specific impact they aim at enhancing. Second, the present paper is one of the few attempts to 
analyze patent influence by presenting a rather broad investigation of the potential 
antecedents. In fact, we discussed the influence of a number of full-text patent indicators, thus 
showing how they differently affect the types of impact. Third, we provided an in-depth 
investigation of a highly complex sector, as the biotechnology industry, where patenting 
activity plays a fundamental role for understanding the dynamics that characterize the 
innovation processes. 
 The analysis offered several practical implications. In fact, by investigating patent 
influence on the basis of different perspectives, we encourage inventing individuals and firms 
to correctly identify the main patenting aim for a more effective resource allocation. We 
showed that patent influence differs across the industrial and organizational domains, thus 
highlighting that strategies and actions need to be carefully designed in the attempt to achieve 
the desired impact given contrasting effects of the considered determinants. For example, 
findings show that joint development activity makes patents technologically relevant within 
the biotechnology industry, while patents with a broader scope exert a stronger influence on 
the technological developments outside biotechnology. The evaluation of a firm’s patent 
portfolio should therefore take into account these differences by weighting patent 
characteristics on the basis of which type of impact should be increased. An understanding of 
the different patenting results may also allow policy makers to define policies and aids to 
better address the required purposes. This is the case of the effect exerted by the use of 
scientific knowledge. A patent that is built more extensively on scientific knowledge 
represents an important base for subsequent technologies (inventions) of the patent’s assignee. 
This provides evidence of the importance to create incentives for firms to strengthen their 
scientific base by, for example, the recruitment of scientists as well as the establishment of 
collaborations with research-oriented organizations. 
It is worth noting the limitations of our analysis. First, despite the extensive and well-
recognized role of forward citations in capturing the influence of patents [11, 12, 20], their 
use has been questioned. In particular, patent citations are often added by examiners rather 
than by assignees [11, 28], and examiners may lack the necessary resources for conducting an 
extensive search of the prior art [28] or decide to withhold citations for strategic reasons [29], 
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hence creating some concerns about the reliability of citation-based indicators. Future 
research efforts should focus on the development of alternative proxies, based, for example, 
on multi-indicator approaches, to assess patent influence. Second, the paper did not 
investigate the potential interdependencies between the full-text patent indicators. Therefore, 
further studies could investigate the interacting effects between the determinants of patent 
influence in order to test the presence of complementary or substitutive effects. Third, the 
proposed research framework could be studied by introducing additional perspectives, such as 
strategic, geographical, and institutional. For instance, the geographical locations of patent 
assignee may contribute to explain differences across patent impact dimensions. Finally, the 
work analyzed only firms operating in the biotechnology industry and located in the US. 
Future studies may validate the results across different sectors and countries. 
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